Immunovant (IMVT) Cash & Equivalents (2018 - 2026)

Immunovant has reported Cash & Equivalents for 9 years, with the latest figure at $902.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 26.35% year-over-year to $902.1 million; the trailing twelve-month figure through Mar 2026 stood at $902.1 million (up 26.35% YoY), and the FY2026 full-year result was $902.1 million, up 26.35% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $902.1 million, down from $994.5 million in the prior quarter.
• The five-year high for Cash & Equivalents was $994.5 million in Q4 2025, with the low at $269.9 million in Q3 2023.
• Historically, Cash & Equivalents has averaged $541.2 million across 5 years, with a median of $493.8 million in 2022.
• Annual changes were most pronounced in 2024 — Cash & Equivalents plunged 45.77% — and 2025, when it soared 165.42%.
• Immunovant's Cash & Equivalents stood at $432.6 million in 2022, then jumped by 59.71% to $690.9 million in 2023, then sank by 45.77% to $374.7 million in 2024, then surged by 165.42% to $994.5 million in 2025, then fell by 9.29% to $902.1 million in 2026.
• The last three Cash & Equivalents figures came in at $902.1 million (Q1 2026), $994.5 million (Q4 2025), and $521.9 million (Q3 2025), per Business Quant data.